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failure with capillary leak syndrome, and 2 had renal failure. Ten
patients had disease resistance or relapse after transplant, and all
have expired. Overall survival to date is 42% (48% for sibling
transplants and 35% for UD) with a range of follow-up from 283
to 1366 days (median 535 days). Acute GVHD grade III or IV was
seen in only 3 patients. After day 100, 27% had extensive GVHD.
The best results were seen in AML or CLL in CR or early relapse
with chemosensitive disease, no AML patient in full blown relapse
survived. This regimen is well tolerated and offers a suitable plat-
form for reduced intensity allogeneic stem cell transplantation.
The beneﬁt(s) of ECP require further testing in the context of
improved radiation therapy, TBI versus TLI (total lymphoid irra-
diation).
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NON-MYELOABLATIVE ALLOGENEIC TRANSPLANTATION WITH ALE-
MTUZUMAB, FLUDARABINE AND CYCLOPHOSPHAMIDE USING 3-6/6
HLA MATCHED DONORS
Rizzieri, D., Chute, J., Horwitz, M., Gasparetto, C., Sullivan, K.,
Long, G., Morris, A., Niedzwiecki, D., Nelson, C. Duke University
Medical Center, Durham, NC.
To broaden the proportion of patients able to undergo allogeneic
therapy, we have investigated the use of 3-6/6 HLA matched
family member donors in combination with donor T cell depletion
in a non-myeloablative preparative regimen. Methods: Seventy
ﬁve matched and 63 mismatched patients received ﬂudarabine 30
mg/m2 IV qd  4, cyclophosphamide 500 mg/m2 IV qd  4, and
alemtuzumab 20 mg IV qd  5 followed by infusion of donor stem
cells. In those with a matched donor, no other GVHD prophylaxis
was used. In those with a 3-5/6 HLA matched donor, mycophe-
nolate 1000 mg po BID was given to the ﬁrst 35 and cyclosporine
was added to the subsequent 28 for 6-8 weeks following transplan-
tation. Results: Patient diagnoses included lymphoma/myeloma
n  36, leukemia/MDS n  63, myeloﬁbrosis/aplasia n  10,
metastatic solid tumors n  29. The median age was 48 (17-70)
with a median follow up of approximately 20 months. Engraftment
occurred in 100% of matched recipients and 92% of mismatched
patients. Eight percent had secondary graft failure as well. Forty six
patients with a matched donor and 23 with a mismatched donor
also had a DLI (range 105-107 CD3 cells/kg). Grade III-IV acute
GVHD occurred in only 7/75 (7%) in the matched setting and
8/63 (13%) of patients. Four percent of matched and 15% of the
mismatched patients developed chronic GVHD and CMV reacti-
vation was common. One hundred day treatment related mortality
for both groups was 10%. Combining both matched and mis-
matched patients, only 12% entered in remission, though 76%
attained a CR. The most common cause of death remained pro-
gressive disease (42%) and GVHD (8%). Despite the high risk
nature of this group, 21 had aplastic anemia/myeloﬁbrosis or leu-
kemia in ﬁrst or second CR and no other available donor other
than their mismatched family member. This group had an encour-
aging 50% 3 year median survival. Phenotypic, spectratype and
TRECs analysis reveals robust recovery by 6 months following
transplantation from peripheral expansion of residual transplanted
T cells Conclusions: The results demonstrate reasonable toler-
ance and reliable engraftment using T cell depleted, 3-6/6 HLA
matched family member donors in a non-myeloablative setting
with low treatment related mortality and severe GVHD. The
future challenge will to be to develop strategies to improve im-
mune recovery to enhance immune-mediated graft-versus-tumor
effect and to minimize the risk of infections.
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THE RELATIONSHIP OF DAY 30 AND DAY 100 DONOR CHIMERISM TO
CLINICAL OUTCOMES FOLLOWING REDUCED-INTENSITY ALLOGENEIC
TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES
Michaelis, L.C., Lin, S.P., Joseph, L., Artz, A.S., Kline, J., Pollea, D.,
Stock, W., Rich, E., Jones, D., Casey, B., Del Cerro, P., Van Besien, K.
University of Chicago, Chicago, IL.
Background: We analyzed chimerism in unfractionated blood
samples of 94 patients enrolled in a prospective phase II trial of
allogeneic transplantation for hematologic malignancies. The aim
was to determine the relationship between chimerism and clinical
outcomes. Methods: All patients received ﬂudarabine, melphalan,
alemtuzumab, post-transplant tacrolimus and peripheral blood
stem cells from related or unrelated donors. PCR-based analysis of
ten polymorphic loci (VNTR) was performed on donor and recip-
ient unfractionated bone marrow aspirates and/or peripheral blood
samples prior to and on approximately day 30 and day 100 after
transplantation. The percentage of donor chimerism and the
change in chimerism between the two time points were examined
for effect on relapse, acute graft vs. host disease, chronic graft vs.
host disease, death, and time to these events. Results: A total of
39/94 (42%) relapsed and 47/94 (50%) have died with a median
follow up of 14 months (range: 1-40 months). Of the 94 patients,
22 had acute GVHD with a severity grading of between II and IV
and 15 experienced chronic GVHD. 86 (91%) of 94 patients had
samples collected for day 30, and 66 (70%) had samples collected
for day 100. The mean chimerism on day 30 samples was 93%
donor (95% CI: 90-97%). There was no signiﬁcant relationship
between the day 30 chimerism and acute GVHD, chronic GVHD,
relapse, death, or time to these events. The mean chimerism for the
66 subjects with available day 100 samples was 88% (95% CI:
83-92%). There was also no relationship found between the day
100 chimerism or its change from the day 30 and chronic GVHD,
relapse, death, or time to these events Conclusions: A ﬂudarabine,
melphalan and alemtuzumab conditioning regimen results in rapid
attainment of high rates of donor chimerism. The percentage of
donor chimerism in unfractionated cell populations did not corre-
late with clinical outcomes in this study. Analysis of T-cell subsets
may be more predictive and is currently being evaluated.
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PRIOR INVASIVE FUNGAL INFECTION DOES NOT PRECLUDE SUCCESS-
FUL ALLOGENEIC TRANSPLANTATION
Hill, B.T., Kondapalli, L., Artz, A., Smith, S., Odenike, O.,
Larson, R.A., Stock, W., Besien, K.V. University of Chicago Section of
Hematology-Oncology, Chicago, IL.
Prior invasive mold infection has historically been considered a
contra-indication for allogeneic stem cell transplantation because
of the high risk of fungal reactivation, and the limited efﬁcacy and
high toxicity of amphotericin-based drugs. Newer antifungal
agents with broad antifungal coverage and an excellent safety and
tolerability proﬁle have dramatically altered the management and
outcome of fungal infections. Here we present a series of 22
consecutive patients with hematologic malignancy and prior inva-
sive fungal infection that underwent T-cell depleted allogeneic
stem cell transplantation at the University of Chicago Hospitals
between 2002 and 2005. Fifteen patients had AML, three had
ALL, two had large cell lymphoma and one each had CLL or
MDS. Their median age was 52 (range 23-68). Eleven patients had
HLA-identical sibling donors, ten had unrelated or mismatched
related donors, and one had a syngeneic donor. Seventeen patients
participated in a prospective study of ﬂudarabine-melphalan-ale-
mtuzumab conditioning (J Clin Oncol 2005;23:5728). Six patients
received various other conditioning regimens containing alemtu-
zumab. Post-transplant GVHD prophylaxis was tacrolimus in all
patients. All had suffered probable or proven invasive aspergillus
infection prior to transplant, involving the lungs in twenty, and the
sinuses in two. All had received intensive antifungal treatment
prior to transplant. They continued such treatment during trans-
plant and for a prolonged period after transplant. Twenty of the 22
patients engrafted. Nine died; three from relapse and one each
from sepsis, cardiac arrest, veno-occlusive disease, fungal pneumo-
nia, PTLD, and multi-organ failure. Three patients experienced
recurrent fungal infection, with one death. Thirteen patients re-
main alive with a median follow-up for survivors of 284 days (range
274-1124). We conclude that in the modern antibiotic era, prior
invasive fungal infection should not preclude the use of stem cell
transplantation as treatment for hematologic malignancy.
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